Evofem Biosciences (EVFM) AI Stock Analysis

• Market Cap: $1.18M
• Dividend Yield: N/A
• Average Volume (3M): 589.38K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.16
• Revenue Growth: 3.67%
• EPS Growth: 91.67%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 126,685,930
• 10 Day Avg. Volume: 412,838
• 30 Day Avg. Volume: 589,380
• PEG Ratio: <0.01
• Price to Book (P/B): -0.01
• Price to Sales (P/S): 0.05
• P/FCF Ratio: -0.24
• Enterprise Value/Market Cap: 56.37
• Enterprise Value/Revenue: 5.19
• Enterprise Value/Gross Profit: 6.53
• Enterprise Value/Ebitda: -24.08
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.01 ▲(0.00% Upside)

The score is held down primarily by weak financial fundamentals—declining revenue, ongoing net losses, negative free cash flow, and a highly pressured balance sheet with negative equity and sizeable debt. Valuation is difficult to support because the company is loss-making (negative P/E) and lacks a dividend yield, while technical analysis cannot be evaluated due to missing indicator data.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand for Evofem's products, particularly Phexxi, suggesting potential for future expansion.

Product Innovation

Evofem's focus on non-hormonal contraceptive solutions positions it well in a growing niche market, potentially driving long-term competitive advantage.

Market Position

By targeting a specific demographic with unmet needs, Evofem can strengthen its market position and build brand loyalty over time.

Negative Factors

High Leverage

High leverage and negative equity pose significant financial risks, potentially limiting the company's ability to invest in growth and innovation.

Cash Flow Challenges

Persistent negative cash flow indicates reliance on external financing, which could hinder operational flexibility and long-term sustainability.

Profitability Issues

Ongoing profitability challenges highlight operational inefficiencies, which may affect the company's ability to achieve sustainable growth.

Evofem Biosciences Business Overview & Revenue Model

Company Description

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

How the Company Makes Money

Evofem Biosciences generates revenue primarily through the sale of its products, particularly Phexxi, which is marketed to women seeking non-hormonal contraceptive options. The company earns money by distributing Phexxi to healthcare providers and directly to consumers, often utilizing prescription channels. Additionally, Evofem may engage in partnerships with healthcare institutions and pharmaceutical distributors to enhance its market reach and sales capabilities. The company may also explore collaborations or licensing agreements to expand its product offerings and revenue potential. Furthermore, government grants and funding for research initiatives could contribute to its financial resources.

Evofem Biosciences Financial Statement Overview

Summary

Evofem Biosciences is facing significant financial challenges. Despite some revenue growth, the company struggles with profitability and cash flow management. High leverage and negative equity raise concerns about financial stability and solvency. The company needs to address its operational inefficiencies and improve its cash flow generation to ensure long-term viability.

Income Statement

Evofem Biosciences has shown some revenue growth over the years, with a notable increase from $446,000 in 2020 to $19,363,000 in 2024. However, the company has consistently reported negative net income, indicating ongoing profitability challenges. The gross profit margin has improved, but the net profit margin remains negative, reflecting significant operational losses. EBIT and EBITDA margins are also negative, highlighting continued operational inefficiencies.

Balance Sheet

The balance sheet of Evofem Biosciences reveals a highly leveraged position, with a negative stockholders' equity of -$71,257,000 in 2024. The debt-to-equity ratio is not calculable due to negative equity, but the substantial total debt of $45,967,000 indicates high financial risk. The equity ratio is negative, underscoring the company's reliance on debt financing and potential solvency issues.

Cash Flow

Evofem Biosciences has consistently reported negative operating and free cash flows, indicating cash burn and reliance on external financing. The operating cash flow to net income ratio is not meaningful due to negative figures. While there has been some improvement in free cash flow from 2023 to 2024, the overall cash flow situation remains challenging, with negative free cash flow of -$3,899,000 in 2024.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.77M	19.36M	18.22M	16.84M	8.24M	446.00K
Gross Profit	10.14M	15.53M	11.71M	12.42M	4.19M	-1.20M
EBITDA	-2.75M	-6.92M	-16.07M	-82.08M	-165.78M	-141.12M
Net Income	-5.54M	-8.86M	52.98M	-76.70M	-205.19M	-142.31M
Balance Sheet
Total Assets	13.81M	23.79M	10.55M	25.16M	42.51M	109.97M
Cash, Cash Equivalents and Short-Term Investments	0.00	741.00K	580.00K	2.77M	7.73M	71.45M
Total Debt	64.82M	45.97M	43.37M	71.13M	115.68M	85.94M
Total Liabilities	83.98M	95.05M	77.06M	96.96M	142.09M	108.62M
Stockholders Equity	-70.17M	-71.26M	-66.51M	-71.80M	-99.58M	1.35M
Cash Flow
Free Cash Flow	-4.43M	-3.90M	-8.97M	-70.75M	-149.61M	-108.14M
Operating Cash Flow	-4.43M	-3.88M	-8.97M	-70.41M	-146.67M	-105.89M
Investing Cash Flow	-48.00K	-569.00K	-4.00K	-341.00K	-2.69M	6.23M
Financing Cash Flow	4.65M	4.62M	4.78M	61.94M	90.69M	155.29M

Evofem Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DARE	50 Neutral	$27.58M	-4.37	―	―	―	―
EVFM	44 Neutral	$1.18M	-0.17	―	―	3.67%	91.67%
XTLB	39 Underperform	$9.03M	-8.82	―	―	―	65.45%

Evofem Biosciences Corporate Events

Evofem Biosciences posts updated corporate investor presentation

Evofem Biosciences, Inc. reported that it periodically shares slide presentations with the investment community at industry and other conferences to provide updates and summaries of its business. The company has made its current corporate slide deck available to investors by posting it on the investor section of its website and noted that the materials, furnished via a recent regulatory filing, are not deemed filed for liability purposes and may be updated at the company’s discretion.

The most recent analyst rating on (EVFM) stock is a Sell with a $0.01 price target. To see the full list of analyst forecasts on Evofem Biosciences stock, see the EVFM Stock Forecast page.

Evofem Biosciences Holds Annual Meeting, Votes on Key Proposals

Evofem Biosciences held its Annual Meeting on November 26, 2025, where various proposals were voted on by the stockholders. Key outcomes included the election of four directors to serve until 2028, approval of executive compensation, the 2025 Equity Incentive Plan, and a reverse stock split amendment. Additionally, BPM LLP was ratified as the independent registered public accounting firm for 2025. These decisions reflect strategic moves to strengthen corporate governance and financial structuring, potentially impacting the company’s future operations and market positioning.

Evofem Biosciences Ends Merger with Aditxt, Refocuses Strategy

On October 20, 2025, Evofem Biosciences announced the termination of its merger agreement with Aditxt, Inc. after shareholders did not approve the proposal. The company is now focusing on regaining a national listing for its stock and securing growth capital to enhance its sales trajectory and achieve sustainable positive EBITDA by 2027. Evofem plans to continue its collaboration with Aditxt to commercialize diagnostic tests for women’s health conditions.

Evofem Biosciences Amends Securities Purchase Agreement

On October 13, 2025, Evofem Biosciences amended its Securities Purchase Agreement with Adjuvant Global Health Technology Fund, updating the maturity date of certain convertible promissory notes. This amendment impacts the company’s financial agreements, potentially affecting its operational flexibility and stakeholder relations.